Getting started is simple

Your GLP-1 journey starts with one download

Through your employer benefits, you now have access to the eMed GLP-1 Pilot Program. Download the eMed app to complete your at-home blood collection and unlock your program.

Enter access code:  UMiami

app store icongoogle market

Scan for IOS

Scan for Android

Getting started

‍

01

Download the eMed app to order your at-home Screening Kit

Your kit ships directly to you. After downloading the eMed app, enter your access code "UMiami" during registration to activate your account. When your kit arrives, scan the QR code to be guided through your at-home blood collection.

02

Return your sample and receive your lab results

eMed offers two convenient return options: same-day FedEx drop-off or next-day pickup using the pre-paid box in your kit. Independent licensed clinicians then review your sample and determine your eligibility for treatment.** Your lab results will be available in the eMed app.

03

Get your prescription and start your medication

If prescribed, your medication will be delivered directly to your home. You’ll then complete your first weekly check-in through the eMed app. Ongoing support is available 24/7 whenever you need it.

‍

**Prescription medications are available only after an independent clinical evaluation by a licensed healthcare professional. Eligibility is not guaranteed. Individual health information and participation data are not shared with your employer.

Helping You Improve Your Health Confidently & Privately

Whether you’re just starting or already on your GLP-1 journey

Ongoing, independent clinical care

At-home convenience

Branded, FDA-approved medication1

24/7 side effect support

Reminders & progress tracking

Lifestyle guidance through Thrive Global

1 Prescription medications are available only after an independent clinical evaluation by a licensed healthcare professional. Eligibility is not guaranteed. GLP-1 medications are prescription drugs. Important Safety Information: https://www.emed.com/important-safety-information

eMed How-To: Registration & Member Experience

0:00

how it works

The eMed Member Experience

‍

Start Your Journey

Member enrolls via eMed app and receives a screening kit

1. Account setup

Fill out user information and accept HIPAA consent.

2. Treatment selection

Select preferred medication option.

3. Kit shipment

eMed At-Home Screening Kit is shipped directly to user’s door.

4. Scan QR code

Initiate screening kit setup securely through the app.

5. Capture vitals

Log weight and upload a full body image for clinical baseline.

6. Medical history

Complete a health questionnaire for personalized treatment plan and ensure clinical safety throughout the journey.

Guided Medical Intake

A complete, clinician-guided intake — all from home.

1. 15–20 min process

Efficient at-home experience designed for user convenience.

2. Complete kit

Includes every component needed for successful blood collection.

3. Step-by-step

Clear, simple instructions from a human proctor who guides the user through the process.

Clinical Review & Delivery

Interactive clinical evaluation & results

1. Lab analysis

Push notification alerts the user once the lab report is processed and ready for review.

2. Medication scan

Access comprehensive lab findings directly within the eMed app.

3. Clinical review

Real-time symptom reporting triggers clinical intervention when needed.

4. Medication delivery

Once qualified, GLP-1 medication is prescribed and delivered directly to the user's doorstep, ensuring a seamless start to their clinical weight management journey.

Weekly Check-Ins

Helping users stay on track — every week, every step.

1. Weight capture

Users log their current weight weekly to visualize progress and stay on track with goals.

2. Medication scan

Simple QR scanning confirms the correct GLP-1 dose is being administered and tracked.

3. Side effects

Real-time symptom reporting allows for clinical intervention when needed.

4. Comprehensive reporting

All weekly check-in data rolls into a detailed health dashboard, visible only to the employer.

Side Effect Management

1. User reports side effects

Users can log symptoms directly through the app — any time, day or night.

2. Clinical review

Medical professionals review symptoms and determine the appropriate next step.

3. Active messaging

Direct communication between user and clinician for clarity.

4. Medication guidance

Prescribing relevant medication to manage side effects.

Seamless Monthly Refill Process

1. Request or delay

Users can manage their refill timing or consult FAQs.

2. Health check-in

A quick questionnaire covers side effects and medical history updates before each refill.

3. Dose adjustment

Option to request dosage changes based on clinical progress.

4. Fulfillment

Automated shipping confirmation once the refill is processed.

Continuous Progress Monitoring

1. Visual lab reports

Biomarker trends, visualized over time.

2. Weight tracking

See progress against clinical weight loss goals.

3. Dose milestones

Track dose milestones and celebrate health outcomes along the way.

4. Health summary

A running summary of health status and improvements — all in one place.

Frequently asked member questions

The eMed GLP-1 Pilot Program

The eMed Pilot Weight Management Program enables University of Miami to support employees and eligible adult dependents 18+ years old with a comprehensive weight management solution. The program provides access to GLP-1/GIP weight loss medications through the following process:

  1. The eligible participant signs up for the program.  Please note: participants must be age 18 or older and enrolled in a University of Miami Aetna medical plan, and the employee must be in active employment. 
  2. The participant receives and completes an onboarding kit, which includes a blood draw.
  3. If deemed clinically eligible for the program, the participant is issued a prescription. (If the member is deemed clinically ineligible, they will receive an email letting them know.)
  4. The participant receives the medication directly to their provided address, fulfilled via mail order pharmacy.
  5. The participant begins weekly check-ins by logging their weight and medication dosage.
  6. When a refill is needed, the participant connects with a clinician, who coordinates the prescription renewal and delivery to the participant.
  7. Every six months, the participant receives a follow-up blood kit to monitor changes in their health metrics over time.

‍

To be eligible for the University of Miami Weight Management Program by eMed, participants must be age 18 or older, enrolled in a University of Miami Aetna medical plan, and the employee must be in active employment. Additional clinical eligibility criteria, as defined by the FDA, also apply.

GLP-1/GIP is a hormone that is made by the small intestine. It has several roles, including:

  • Triggering insulin release from the pancreas: Insulin is an essential hormone that allows the body to use the food eaten for energy. It lowers the amount of glucose (sugar) in the blood. If there is not enough insulin, blood sugar increases, leading to diabetes.
  • Blocking glucagon secretion: Glucagon is a hormone that the body uses to raise blood sugar levels when necessary. So GLP-1/GIP prevents more glucose from going into the bloodstream.
  • Slowing stomach emptying: Slower digestion means that the body releases less glucose (sugar) from the food eaten into the bloodstream.
  • Increasing how full someone feels after eating (satiety): GLP-1/GIP affects areas of the brain that process hunger and satiety.

GLP-1/GIP agonist medications work by mimicking this hormone. In medication terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1/GIP medications bind to GLP-1/GIP receptors to trigger the effects (or roles) of the GLP-1/GIP hormone. The higher the dose of the GLP-1/GIP agonist, the more extreme the effects. The satiety effect of GLP-1 agonists reduces food intake, appetite and hunger. These combined effects often result in weight loss. Individuals generally take GLP-1/GIP injections for an extended period of time, but the duration varies by individual.

Compounded drugs do not have the same safety, quality and effectiveness assurances as FDA-approved drugs. eMed does not offer compounded GLP-1/GIP medication.

The current U.S. Food and Drug Administration (FDA)-approved GLP-1/GIP medications for weight management in the eMed program are Wegovy (both injectable and oral formulations), Zepbound, and Foundayo. For specific questions regarding these medications, participants should visit the manufacturers’ websites.

‍

 Individuals currently on a GLP-1/GIP for weight loss are invited to join eMed to transition their care for these medications.  During enrollment, eMed will ask whether the participant is taking GLP-1/GIPs.  If so, the eMed app will request an upload of the current prescription so eMed’s clinical partners can take that information into account when evaluating eligibility.

No. The eMed program focuses on weight management. Employees and covered dependents enrolled in a University of Miami medical plan may discuss the suitability of a GLP-1 for non-weight loss indications with their primary care provider and/or specialist. If prescribed by a primary care provider or specialist for a non-weight-loss indication, the medication could potentially be covered under the University of Miami medical and pharmacy plan, subject to its terms, formulary, and requirements.

‍

No. The program only provides access to board-certified clinicians who will prescribe GLP-1/GIP medication for weight management, manage refills and any dose changes, as well as assist if the participant experiences any side effects. If a participant receives weight loss medications prescribed by eMed as part of this program, participants are encouraged to keep their primary care clinician informed.

The University of Miami provides the eMed program to its employees and their eligible adult dependents 18+ years old who are covered under a University of Miami Aetna medical plan. The eMed program includes a medical intake kit, lab work, access to licensed clinicians, 24/7 side effect support, ongoing progress tracking, and wellness content through Thrive. Eligible University of Miami participants pay for their monthly medication at a cost of $199 per prescription.

No. The $199 per prescription cost does not apply to your University of Miami health plan deductible or out-of-pocket maximum. It is, however, an eligible FSA and HSA expense, just like other prescriptions.

Participants should download the eMed app, and use the code “UMiami” to access the program.

The screening process takes approximately 30 minutes.

The participant will need to provide their full legal name on file with the University of Miami, date of birth, email address and physical address.

As part of the process, a clinician will review both your medical history and your sample blood test to determine whether you qualify to take a GLP-1/GIP medication. These medications have very specific requirements for when they can be prescribed and there are specific situations where they may not be the best option for you medically. Your clinician will review your medical history and your lab results to determine if you are medically eligible to take the prescription.

Members must complete their bloodwork through the eMed solution to qualify for and participate in the program. The value of using eMed for your labwork is you have a consistent means of evaluating your progress in the program. In addition, outside lab results, recent physicals, or standard biometric/wellness screenings may have similar metrics, but not all of the metrics eMed captures.

During the screening, participants will be asked to step on a scale and show their weight, take a full body picture, and complete the blood collection. The full body picture is used to determine body type and can be an indicator of cardiometabolic disease. The blood draw uses a needleless Tasso device, which takes the blood from the upper arm, just below the shoulder. The blood collection is taken on camera, so having a short-sleeved shirt on makes it easier to complete the process on camera while maintaining privacy.

The blood collection is taken using a needleless Tasso device. An eMed virtual proctor guides the participant through the process, including warming the arm, cleaning the area with an alcohol swab, and collecting the sample. It is recommended to drink one to two glasses of water prior to collection. It may take up to two minutes for blood to begin flowing into the vial.

The virtual proctor will arrange a FedEx pickup of the blood sample, which should occur as soon as possible. eMed will provide pickup details after the collection is complete. If pickup is scheduled more than two hours later, the sample should be stored in a cool, dry place until pickup.

Once the blood sample is picked up, it takes three to five days for the sample to be processed by the lab and for a clinician to review results. Participants will be notified by email when a decision has been made. If participants are not approved for the eMed program, they will be notified within three to five business days from when the sample is picked up.

The eMed app supports real-time in-app messaging with a clinician within the eMed clinical network. In addition, participants may also request a live conversation or contact eMed Customer Support at 1-800-914-6185 or support@emed.com to request a live conversation.

‍

‍

Your prescription will be directly filled by eMed’s mail order pharmacy. The licensed eMed clinician will send your prescription and refills directly to the mail order pharmacy for fulfillment.

During the weekly check-in, participants will be asked to log their weight both audibly and by taking a picture of the scale. They will also scan their medication and will be reminded about what to do if they experience side effects. The process takes about one minute.

If a weekly check-in is missed, participants will receive an email that provides the next steps. If unable to complete the check-in, a new reminder for a weekly check-in will occur the following week on the regularly scheduled check-in day. If no weekly check-ins occur in a 55 day period, your enrollment in the program will be terminated.

Participants should report side effects through the eMed app, log severity and request clinician support. In case of a medical emergency, they should call 911.

Blood tests are expected to be repeated every six months to monitor progress.

The duration of medication use varies by individual and is determined based onclinical evaluation, treatment response, and ongoing health goals. Some members may use GLP-1/GIP medications long-term as part of a sustained weight management plan, while others may taper or discontinue under the guidance of their clinician once appropriate health outcomes are achieved. Continued eligibility and treatment duration are regularly assessed through ongoing clinical monitoring and check-ins.

‍

‍

If a member wishes to change their dose or medication, they can discuss this with their assigned clinician through the eMed app. All adjustments are made based on clinical assessment, safety considerations, and the member’s response to treatment. The clinician will evaluate the request and determine the most appropriate adjustment to ensure safe and effective care.

If a participant does not complete a check-in or request a refill for 8 weeks, their enrollment in the eMed program is automatically terminated.

‍

Completing a check-in or requesting a refill. Doing either one within the 8-week window keeps enrollment active.

‍

It is automatic. Once a participant reaches 8 weeks without a check-in or a refill request, enrollment ends.

‍

Yes. The participant receives a notification that outlines the participation requirements they missed.

‍

Clinical safety. If a participant stops taking a GLP-1/GIP medication for more than 8 weeks, the dose they were previously prescribed may no longer be safe or appropriate for them.

‍

Starting the onboarding process again allows the clinical team to review the participant’s current health information and determine the safest way to restart treatment.

‍

Yes. A participant can re-enroll by contacting the eMed support team.

‍

No. There is no waiting period, and a participant may re-enroll at any time.

‍

The participant must re-register and complete the full onboarding process again.

‍

Yes. Re-enrollment requires new lab work and new clinical assessments as part of the standard onboarding process.

‍

eMed will ensure confidentiality about the participation of individual plan members in the program. HIPAA-authorized employer benefits team members will receive only aggregate information about participation.

For clinical (including clinical eligibility) or program questions, members may reach out to eMed at 1-800-914-6185 or support@emed.com. For program eligibility, medical enrollment, or HR policy inquiries, members may reach out to HR-Total Rewards at 305-284-3004.

A health program for a unique

health journey

Whether you’re just starting or already on your GLP-1 journey

Your journey begins here.

app store icongoogle market